INFORMATION BY CANCER TYPE

Leukemia

FDA Approves Rituxan Hycela for Blood Cancers
BY Jason M. Broderick
Rituxan Hycela (rituximab) was granted approval by the Food and Drug Administration (FDA) for adult patients with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL) and previously untreated and previously treated chronic lymphocytic leukemia (CLL).
Expert Discusses Advances in Treating CLL
BY Gina Columbus
Imbruvica (ibrutinib) continues to demonstrate benefit in patients with chronic lymphocytic leukemia (CLL) who had at least one prior therapy, according to a four-year follow-up of the RESONATE study, which compared the BTK inhibitor to Arzerra (ofatumumab).
 
New Drug Granted a Priority Review for AML Treatment
BY Jason Harris
VYXEOS (CPX-351), a novel injection, was granted a new drug application (NDA) by the Food and Drug Administration (FDA), granting the drug a priority review for the treatment of acute myeloid leukemia (AML), according to Jazz Pharmaceuticals, the producer of the drug.
Seeking a Complete Response in Hematologic Cancers
BY Jason Harris
Experts discuss how to have the best chances for a complete response for patients with chronic lymphocytic leukemia (CLL) who developed Hodgkin lymphoma (HL). 
FDA Approves Rydapt for AML
BY Jason M. Broderick
The Food and Drug Administration has approved Rydapt (midostaurin) for acute myeloid leukemia (AML).
Waiting for the Next Breakthrough: Living With a Chronic Blood Cancer
BY Tara Haelle
"Neither feels guilty about surviving — although both have had plenty of reminders that they’re dealing with cancer — and both have found ways to continue enjoying life." 
A New Formulation for Rituxan Moves Ahead With FDA Committee Vote
BY Jason M. Broderick
All members of the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted to approve Rituxan for the treatment of some blood cancers.
Looking Ahead: What's New In CAR T-Cell Therapy for Hematologic Malignancies
BY Rebecca Bernaski
Jim Kochenderfer, M.D., lends insight to the future of CAR T-cell therapy for hematologic malignancies.
Debunking the Myths of Stem Cell Donation
BY Allie Casey
Just one person can make a difference for patients with blood cancer.
A New Chapter Begins With CML
BY Tara Haelle
Hope is growing for patients who are living with CML. 
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Leukemia CURE discussion group.
Search Cancer Drugs & Terms
Treatment
Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
Adult Acute Lymphoblastic Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of adult acute lymphoblastic leukemia.
Adult Acute Myeloid Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of adult acute myeloid leukemia.
Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of childhood acute lymphoblastic leukemia.
Chronic Lymphocytic Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of chronic lymphocytic leukemia.
Chronic Lymphocytic Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of chronic lymphocytic leukemia.
Chronic Myelogenous Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of chronic myelogenous leukemia.
Hairy Cell Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of hairy cell leukemia.
x